222 related articles for article (PubMed ID: 29497840)
1. IL-17 inhibition: is it the long-awaited savior for alopecia areata?
Ramot Y; Marzani B; Pinto D; Sorbellini E; Rinaldi F
Arch Dermatol Res; 2018 Jul; 310(5):383-390. PubMed ID: 29497840
[TBL] [Abstract][Full Text] [Related]
2. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
Trüeb RM; Dias MFRG
Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
[TBL] [Abstract][Full Text] [Related]
3. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing.
Suárez-Fariñas M; Ungar B; Noda S; Shroff A; Mansouri Y; Fuentes-Duculan J; Czernik A; Zheng X; Estrada YD; Xu H; Peng X; Shemer A; Krueger JG; Lebwohl MG; Guttman-Yassky E
J Allergy Clin Immunol; 2015 Nov; 136(5):1277-87. PubMed ID: 26316095
[TBL] [Abstract][Full Text] [Related]
4. Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases.
Garzorz N; Alsisi M; Todorova A; Atenhan A; Thomas J; Lauffer F; Ring J; Schmidt-Weber C; Biedermann T; Eyerich S; Eyerich K
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2429-35. PubMed ID: 26416203
[TBL] [Abstract][Full Text] [Related]
5. A novel therapeutic paradigm for patients with extensive alopecia areata.
Renert-Yuval Y; Guttman-Yassky E
Expert Opin Biol Ther; 2016 Aug; 16(8):1005-14. PubMed ID: 27164008
[TBL] [Abstract][Full Text] [Related]
6. T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-α) in patients with alopecia areata: association with clinical type and severity.
Atwa MA; Youssef N; Bayoumy NM
Int J Dermatol; 2016 Jun; 55(6):666-72. PubMed ID: 26235375
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases.
Malik K; Guttman-Yassky E
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S62-S64. PubMed ID: 29273110
[TBL] [Abstract][Full Text] [Related]
8. B cell activating factor and T-helper 17 cells: possible synergistic culprits in the pathogenesis of Alopecia Areata.
Elela MA; Gawdat HI; Hegazy RA; Fawzy MM; Abdel Hay RM; Saadi D; Shaker O
Arch Dermatol Res; 2016 Mar; 308(2):115-21. PubMed ID: 26796544
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata.
Guttman-Yassky E; Nia JK; Hashim PW; Mansouri Y; Alia E; Taliercio M; Desai PN; Lebwohl MG
Arch Dermatol Res; 2018 Oct; 310(8):607-614. PubMed ID: 30121698
[TBL] [Abstract][Full Text] [Related]
10. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata.
Gong Y; Zhao Y; Zhang X; Qi S; Li S; Ye Y; Yang J; Caulloo S; McElwee KJ; Zhang X
Exp Dermatol; 2020 Mar; 29(3):231-238. PubMed ID: 30047620
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata.
Aşkın Ö; Yücesoy SN; Coşkun E; Engin B; Serdaroğlu S
An Bras Dermatol; 2021; 96(5):551-557. PubMed ID: 34281739
[TBL] [Abstract][Full Text] [Related]
12. Etiopathogenesis of alopecia areata: Why do our patients get it?
Wang E; McElwee KJ
Dermatol Ther; 2011; 24(3):337-47. PubMed ID: 21689243
[TBL] [Abstract][Full Text] [Related]
13. iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata.
Ghraieb A; Keren A; Ginzburg A; Ullmann Y; Schrum AG; Paus R; Gilhar A
J Autoimmun; 2018 Jul; 91():61-72. PubMed ID: 29680372
[TBL] [Abstract][Full Text] [Related]
14. An update on alopecia areata.
Kos L; Conlon J
Curr Opin Pediatr; 2009 Aug; 21(4):475-80. PubMed ID: 19502982
[TBL] [Abstract][Full Text] [Related]
15. Understanding autoimmunity of vitiligo and alopecia areata.
Rork JF; Rashighi M; Harris JE
Curr Opin Pediatr; 2016 Aug; 28(4):463-9. PubMed ID: 27191524
[TBL] [Abstract][Full Text] [Related]
16. Serum level of interleukin-17A in patients with alopecia areata and its relationship to age.
El-Morsy EH; Eid AA; Ghoneim H; Al-Tameemi KA
Int J Dermatol; 2016 Aug; 55(8):869-74. PubMed ID: 26475394
[TBL] [Abstract][Full Text] [Related]
17. Alopecia areata in patients with inflammatory bowel disease: an overview.
Sobolewska-Włodarczyk A; Włodarczyk M; Fichna J; Wiśniewska-Jarosińska M
Folia Med Cracov; 2016; 56(1):5-12. PubMed ID: 27513834
[TBL] [Abstract][Full Text] [Related]
18. T lymphocyte subpopulations in alopecia areata and psoriasis: identification with monoclonal antibodies and Fc receptors.
Gu SQ; Petrini B; Ros AM; Thyresson N; Wasserman J
Acta Derm Venereol; 1983; 63(3):244-6. PubMed ID: 6192643
[TBL] [Abstract][Full Text] [Related]
19. Comparison of interleukin-17- producing cells in different clinical types of alopecia areata.
Tojo G; Fujimura T; Kawano M; Ogasawara K; Kambayashi Y; Furudate S; Mizuashi M; Aiba S
Dermatology; 2013; 227(1):78-82. PubMed ID: 24008930
[TBL] [Abstract][Full Text] [Related]
20. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
